Skip to main content
Caplight Logo









Gyala Therapeutics

Gyala Therapeutics

Private
BarcelonaHealthcare & Life Scienceshttps://gyalatx.com/

Last Round

Grant

Feb 11, 2026

Total Funding Raised

$9.64M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Gyala Therapeutics is a biotechnology company developing next-generation immunotherapies for hematological cancers with high unmet need.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2G

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

CAR-T cell therapyCAR-T therapycell therapyfirst-in-class therapyacute myeloid leukemiaAMLT-cell acute lymphoblastic leukemiaT-ALLCD84 targetautologous cell therapycancer immunotherapyleukemia treatmentblood cancer treatmenthematologic cancergene therapyoncologyclinical-stage biotechnology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Gyala Therapeutics Comparables

Compare Gyala Therapeutics with similar companies based on industry and business-model similarity.

Gyala Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
OneChain Immunotherapeutics
86%
iCell Gene Therapeutics
76%
AvenCell
73%

Gyala Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 11, 2026
SeedSep 15, 2025
VC RoundOct 14, 2024
SeedMay 26, 2020

Key People

Founding team and executive leadership

Claudio Santos

Chief Executive Officer

Executive Team

Gyala Therapeutics Investors

Notable investors and investment history

Gyala Therapeutics investors
InvestorRounds
Nara CapitalVC Round, Seed
Center for Technological Development and InnovationVC Round, Seed
Invivo PartnersVC Round, Seed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 15, 2025

    First-in-class therapy targets CD84, showing preclinical efficacy in leukemias.

  • Sep 15, 2025

    $4M raised from Invivo Partners and Nara Capital.

Gyala Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Gyala Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Gyala Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBarcelona
Employee Range8
Year Founded2020
Last FundingFeb 11, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?